Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NICE Ltd (NICE) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance

SELLAS Life Sciences Group Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

NICE Ltd vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? NICE Ltd trades at $117.31 (market cap $6.83B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: NICE Ltd is far larger — about 3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and NICE Ltd is more actively traded (444,610 versus 3,128,960). Which is the better fit depends on your goals.

NICESLS
Market Cap
$6.83B$2.28B
Volume
444,6103,128,960
Sector
TechnologyHealth
52-Week High
$137.68$15.46
52-Week Low
$83.15$1.39
Typical Hold Time
15 Days—
Enterprise Value
$6.57B$2.15B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NICE Ltd

NICE (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $2.95 billion in 2025, though net income is projected to decline in 2026. Recent news highlights leadership in AI-driven contact center platforms and positive institutional buying interest.

The outlook for NICE is positive, supported by AI revenue growth and a reasonable valuation, but investors face risks from margin compression and earnings volatility. The stock's proximity to resistance at $118 suggests near-term consolidation may occur before further upside.

SELLAS Life Sciences Group Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NICE
0% Buy100% Sell
Avg holding period · 15 Days
SLS

No sentiment data available yet.

About NICE Ltd

NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.

Read more on NICE →

About SELLAS Life Sciences Group Inc. Common Stock

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.

Read more on SLS →